Drug Trial Radar · NCT05257265
A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
Last checked: Nov 20, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
459
Actual
Start
Feb 2, 2022
Primary completion
Sep 29, 2023
Study completion Oct 5, 2023
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Feb 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial was conducted to evaluate the efficacy and safety of the Centanafadine once daily (QD) extended release (XR) capsules in adolescent participants (13 - 17 years, inclusive) with attention-deficit/hyperactivity disorder (ADHD).
Conditions
- Attention-Deficit/Hyperactivity Disorder
Interventions
Centanafadine HydrochlorideDrug
Capsule
PlaceboOther
Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Attention-Deficit/Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5)Time frame: From baseline to week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
For additional information regarding sites, contact 844-687-8522
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.